The DOI matches its Crossref record; 97 of the 97 references it cites were found in a registry or an index.
New Insights into Mechanisms of Cisplatin Resistance: From Tumor Cell to Microenvironment
Open accessAbstract
Although cisplatin has been a pivotal chemotherapy drug in treating patients with various types of cancer for decades, drug resistance has been a major clinical impediment. In general, cisplatin exerts cytotoxic effects in tumor cells mainly through the generation of DNA-platinum adducts and subsequent DNA damage response. Accordingly, considerable effort has been devoted to clarify the resistance mechanisms inside tumor cells, such as decreased drug accumulation, enhanced detoxification activity, promotion of DNA repair capacity, and inactivated cell death signaling. However, recent advances in high-throughput techniques, cell culture platforms, animal models, and analytic methods have also demonstrated that the tumor microenvironment plays a key role in the development of cisplatin resistance. Recent clinical successes in combination treatments with cisplatin and novel agents targeting components in the tumor microenvironment, such as angiogenesis and immune cells, have also supported the therapeutic value of these components in cisplatin resistance. In this review, we summarize resistance mechanisms with respect to a single tumor cell and crucial components in the tumor microenvironment, particularly focusing on favorable results from clinical studies. By compiling emerging evidence from preclinical and clinical studies, this review may provide insights into the development of a novel approach to overcome cisplatin resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607 · cited 2×
“Recently, clinical benefits from combination treatments using platinum-based therapies and TME-targeting agents, such as antiangiogenic drugs and ICIs, have proven the considerable value of these agents for circumventing CDDP resistance in patients with cancer [84,85,101,102].”
Cisplatin in cancer therapy: Molecular mechanisms of action
Dasari, S., & Bernard Tchounwou, P. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.025 · Cited by 5,537
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088
The extracellular matrix: A dynamic niche in cancer progression
Lu, P., Weaver, V. M., & Werb, Z. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201102147 · Cited by 3,024
Drug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805
Hypoxia in cancer: significance and impact on clinical outcome
Vaupel, P., & Mayer, A. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9055-1 · Cited by 2,240
Denkert, C., Loibl, S., Noske, A., Roller, M., Müller, B. M., Komor, M., Budczies, J., Darb-Esfahani, S., Kronenwett, R., Hanusch, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.7370 · Cited by 1,762
Cisplatin: The first metal based anticancer drug
Ghosh, S. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.102925 · Cited by 1,751
Reck, M., von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V., Hirsh, V., Leighl, N., Mezger, J., Archer, V., Moore, N., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5466 · Cited by 1,505
Macrophages and Therapeutic Resistance in Cancer
Ruffell, B., & Coussens, L. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.015 · Cited by 1,474
The emerging role of the Nrf2–Keap1 signaling pathway in cancer
Jaramillo, M. C., & Zhang, D. D. (2013) · Genes & Development · doi:10.1101/gad.225680.113 · Cited by 1,297
Dysfunctional KEAP1–NRF2 Interaction in Non-Small-Cell Lung Cancer
Singh, A., Misra, V., Thimmulappa, R. K., Lee, H., Ames, S., Hoque, M. O., Herman, J. G., Baylin, S. B., Sidransky, D., Gabrielson, E., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030420 · Cited by 1,060
Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2
Wang, X.-J., Sun, Z., Villeneuve, N. F., Zhang, S., Zhao, F., Li, Y., Chen, W., Yi, X., Zheng, W., Wondrak, G. T., et al. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn095 · Cited by 839
How Do Cytotoxic Lymphocytes Kill Cancer Cells?
Martínez-Lostao, L., Anel, A., & Pardo, J. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0685 · Cited by 717
The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance
Bouwman, P., & Jonkers, J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3342 · Cited by 615
Cisplatin resistance and opportunities for precision medicine
Amable, L. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.01.001 · Cited by 589
Safaei, R., Larson, B. J., Cheng, T. C., Gibson, M. A., Otani, S., Naerdemann, W., & Howell, S. B. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0102 · Cited by 564
Eastman, A. (1987) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(87)90009-x · Cited by 539
Tannock, I. F., Lee, C. M., Tunggal, J. K., Cowan, D., & Egorin, M. J. (2002) · PubMed · Cited by 505
Jinushi, M., Chiba, S., Yoshiyama, H., Masutomi, K., Kinoshita, I., Dosaka-Akita, H., Yagita, H., Takaoka, A., & Tahara, H. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1106645108 · Cited by 479
DNA repair pathways and cisplatin resistance: an intimate relationship
Rocha, C. R. R., Silva, M. M., Quinet, A., Cabral-Neto, J. B., & Menck, C. F. M. (2018) · Clinics · doi:10.6061/clinics/2018/e478s · Cited by 446
The tumor microenvironment is a dominant force in multidrug resistance
Correia, A. L., & Bissell, M. J. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.01.006 · Cited by 443
Qin, X., Guo, H., Wang, X., Zhu, X., Yan, M., Wang, X., Xu, Q., Shi, J., Lu, E., Chen, W., et al. (2019) · Genome Biology · doi:10.1186/s13059-018-1604-0 · Cited by 431
Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer
Wang, W., Kryczek, I., Dostál, L., Lin, H., Tan, L., Zhao, L., Lu, F., Wei, S., Maj, T., Peng, D., et al. (2016) · Cell · doi:10.1016/j.cell.2016.04.009 · Cited by 422
Halama, N., Michel, S., Kloor, M., Zoernig, I., Benner, A., Spille, A., Pommerencke, T., von Knebel, D. M., Folprecht, G., Luber, B., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0268 · Cited by 420
Strategies for optimizing combinations of molecularly targeted anticancer agents
Dancey, J. E., & Chen, H. X. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2089 · Cited by 365
Tumor pH controls the in vivo efficacy of weak acid and base chemotherapeutics
Gerweck, L. E., Vijayappa, S., & Kozin, S. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0024 · Cited by 362
Cisplatin-Induced Antitumor Immunomodulation: A Review of Preclinical and Clinical Evidence
de Biasi, A. R., Villena-Vargas, J., & Adusumilli, P. S. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1298 · Cited by 342
Barlesi, F., Scherpereel, A., Rittmeyer, A., Pazzola, A., Ferrer Tur, N., Kim, J.-H., Ahn, M.-J., Aerts, J. G. J. V., Gorbunova, V., Vikström, A., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.3749 · Cited by 323
Enhancing Tumor-Specific Uptake of the Anticancer Drug Cisplatin with a Copper Chelator
Ishida, S., McCormick, F., Smith-McCune, K., & Hanahan, D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.04.011 · Cited by 288
Castells, M., Thibault, B., Delord, J.-P., & Couderc, B. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13089545 · Cited by 285
Cancer-associated fibroblasts-derived IL-8 mediates resistance to cisplatin in human gastric cancer
Zhai, J., Shen, J., Xie, G., Wu, J., He, M., Gao, L., Zhang, Y., Yao, X., & Shen, L. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.04.002 · Cited by 272
Hanahan, D. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62226-6 · Cited by 271
Song, I.-S., Savaraj, N., Siddik, Z. H., Liu, P., Wei, Y., Wu, C. J., & Kuo, M. T. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1543.3.12 · Cited by 259
Lowery, M. A., Kelsen, D. P., Stadler, Z. K., Yu, K. H., Janjigian, Y. Y., Ludwig, E., D'Adamo, D. R., Salo-Mullen, E., Robson, M. E., Allen, P. J., et al. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-0185 · Cited by 245
(1992) · Lung Cancer · doi:10.1016/0169-5002(92)90185-m · Cited by 237
Lewis, A. D., Hayes, J. D., & Wolf, C. R. (1988) · Carcinogenesis · doi:10.1093/carcin/9.7.1283 · Cited by 223
Cabral, H., Nishiyama, N., Okazaki, S., Koyama, H., & Kataoka, K. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.08.022 · Cited by 201
pH and drug resistance in tumors
Raghunand, N., & Gillies, R. J. (2000) · Drug Resistance Updates · doi:10.1054/drup.2000.0119 · Cited by 194
Subcellular targets of cisplatin cytotoxicity: An integrated view
Sancho-Martínez, S. M., Prieto-García, L., Prieto, M., López-Novoa, J. M., & López-Hernández, F. J. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.07.003 · Cited by 183
Jo, Y., Choi, N., Kim, K., Koo, H.-J., Choi, J., & Kim, H. N. (2018) · Theranostics · doi:10.7150/thno.29098 · Cited by 183
Hinoshita, E., Uchiumi, T., Taguchi, K., Kinukawa, N., Tsuneyoshi, M., Maehara, Y., Sugimachi, K., & Kuwano, M. (2000) · PubMed · Cited by 179
Platinum Antitumor Complexes: 50 Years Since Barnett Rosenberg's Discovery
Muggia, F. M., Bonetti, A., Hoeschele, J. D., Rozencweig, M., & Howell, S. B. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.60.7481 · Cited by 177
Interaction of Cisplatin with the Human Organic Cation Transporter 2
Filipski, K. K., Loos, W. J., Verweij, J., & Sparreboom, A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4793 · Cited by 169
Salvagno, C., Ciampricotti, M., Tuit, S., Hau, C.-S., van Weverwijk, A., Coffelt, S. B., Kersten, K., Vrijland, K., Kos, K., Ulas, T., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0298-1 · Cited by 168
Qiao, Y., Zhang, C., Li, A., Wang, D., Luo, Z., Ping, Y., Zhou, B., Liu, S., Li, H., Yue, D., et al. (2018) · Oncogene · doi:10.1038/onc.2017.387 · Cited by 166
Davies, M. S., Berners-Price, S. J., & Hambley, T. W. (2000) · Inorganic Chemistry · doi:10.1021/ic000847w · Cited by 165
Zamboni, W. C., Gervais, A. C., Egorin, M. J., Schellens, J. H. M., Zuhowski, E. G., Pluim, D., Joseph, E., Hamburger, D. R., Working, P. K., Colbern, G., et al. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0719-4 · Cited by 165
Nanotechnology: a promising method for oral cancer detection and diagnosis
Chen, X., Zhang, X., Liu, Q., Zhang, J., & Zhou, G. (2018) · Journal of Nanobiotechnology · doi:10.1186/s12951-018-0378-6 · Cited by 163
Kaina, B., Margison, G. P., & Christmann, M. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0491-7 · Cited by 157
Role of hyaluronan in pancreatic cancer biology and therapy: Once again in the spotlight
Sato, N., Kohi, S., Hirata, K., & Goggins, M. (2016) · Cancer Science · doi:10.1111/cas.12913 · Cited by 145
Tumor Eradication by Cisplatin Is Sustained by CD80/86-Mediated Costimulation of CD8+ T Cells
Nejad, E. B., van der Sluis, T. C., van Duikeren, S., Yagita∥, H., Janssen, G. M. C., van Veelen, P. A., Melief, C. J. M., van der Burg, S. H., & Arens, R. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0881 · Cited by 144
The Role of Tumor Microenvironment in Chemoresistance: 3D Extracellular Matrices as Accomplices
Senthebane, D. A., Jonker, T., Rowe, A., Thomford, N. E., Munro, D., Dandara, C., Wonkam, A., Govender, D., Calder, B., Soares, N. C., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102861 · Cited by 143
Cross-linking of glutathione to DNA by cancer chemotherapeutic platinum coordination complexes
Eastman, A. R. (1987) · Chemico-Biological Interactions · doi:10.1016/0009-2797(87)90004-4 · Cited by 142
Yamasaki, M., Makino, T., Masuzawa, T., Kurokawa, Y., Miyata, H., Takiguchi, S., Nakajima, K., Fujiwara, Y., Matsuura, N., Mori, M., et al. (2011) · British Journal of Cancer · doi:10.1038/sj.bjc.6606071 · Cited by 140
Samimi, G., Varki, N. M., Wilczynski, S. P., Safaei, R., Alberts, D. S., & Howell, S. B. (2003) · PubMed · Cited by 139
Tao, L., Huang, G., Wang, R., Pan, Y., He, Z., Chu, X., Song, H., & Chen, L. (2016) · Scientific Reports · doi:10.1038/srep38408 · Cited by 137
Low toxicity and anticancer activity of a novel liposomal cisplatin (Lipoplatin) in mouse xenografts
Boulikas, T. (2004) · Oncology Reports · doi:10.3892/or.12.1.3 · Cited by 134
Farooq, M. A., Aquib, M., Farooq, A., Khan, D. H., Maviah, M. B. J., Filli, M. S., Kesse, S., Boakye‐Yiadom, K. O., Mavlyanova, R., Parveen, A., et al. (2019) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2019.1604535 · Cited by 134
Long, X., Xiong, W., Zeng, X., Qi, L., Cai, Y., Mo, M., Jiang, H., Zhu, B., Chen, Z., & Li, Y. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1581-6 · Cited by 130
Stemness and chemoresistance in epithelial ovarian carcinoma cells under shear stress
Ip, C. K. M., Li, S.-S., Tang, M. Y. H., Sy, S. K. H., Ren, Y., Shum, H. C., & Wong, A. S. T. (2016) · Scientific Reports · doi:10.1038/srep26788 · Cited by 128
Samuel, P., Mulcahy, L. A., Furlong, F. M., McCarthy, H. O., Brooks, S. A., Fabbri, M., Pink, R. C., & Carter, D. R. F. (2017) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2017.0065 · Cited by 128
Nakayama, K., Kanzaki, A., Terada, K., Mutoh, M., Ogawa, K., Sugiyama, T., Takenoshita, S., Itoh, K., Yaegashi, N., Miyazaki, K., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0454 · Cited by 114
Wakai (2010) · Oncology Reports · doi:10.3892/or_00000721 · Cited by 108
Chemotherapy Broadens the Range of Tumor Antigens Seen by Cytotoxic CD8+ T Cells in Vivo
Jackaman, C., Majewski, D., Fox, S. A., Nowak, A. K., & Nelson, D. J. (2012) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-012-1307-4 · Cited by 105
Wang, L., Li, X., Ren, Y., Geng, H., Zhang, Q., Cao, L., Meng, Z., Wu, X., Xu, M., & Xu, K. (2019) · Cancer Science · doi:10.1111/cas.13998 · Cited by 105
Exploring Novel Methods for Modulating Tumor Blood Vessels in Cancer Treatment
Wong, P., Bodrug, N., & Hodivala‐Dilke, K. (2016) · Current Biology · doi:10.1016/j.cub.2016.09.043 · Cited by 104
Surowiak, P., Materna, V., Kaplenko, I., Spaczyński, M., Dietel, M., Lage, H., & Zabel, M. (2005) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-005-1228-0 · Cited by 98
Cisplatin Cytotoxicity: DNA and Plasma Membrane Targets
Rébillard, A., Lagadic‐Gossmann, D., & Dimanche‐Boitrel, M. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708786242903 · Cited by 94
The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer
Hayden, A. L., Douglas, J., Sommerlad, M., Andrews, L. P., Gould, K., Hussain, S. A., Thomas, G. J., Packham, G., & Crabb, S. J. (2014) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2014.02.006 · Cited by 91
Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer
Kim, E. S., Tang, X., Peterson, D. R., Kilari, D., Chow, C.-W. B., Fujimoto, J., Kalhor, N., Swisher, S. G., Stewart, D. J., Wistuba, I. I., et al. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.04.005 · Cited by 88
Gourley, C., Michie, C. O., Roxburgh, P., Yap, T. A., Harden, S., Paul, J., Ragupathy, K., Todd, R., Petty, R., Reed, N., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.1082 · Cited by 88
El-Khateeb, M., Appleton, T. G., Gahan, L. R., Charles, B. G., Berners‐Price, S. J., & Bolton, A.-M. (1999) · Journal of Inorganic Biochemistry · doi:10.1016/s0162-0134(99)00146-4 · Cited by 84
Miyashita, H., Nitta, Y., Mori, S., Kanzaki, A., Nakayama, K., Terada, K., Sugiyama, T., Kawamura, H., Satō, A., MORIKAWA, H., et al. (2003) · Oral Oncology · doi:10.1016/s1368-8375(02)00038-6 · Cited by 83
Zhang, H., Xie, C., Yue, J., Jiang, Z., Zhou, R., Xie, R., Wang, Y., & Wu, S. (2016) · Molecular Carcinogenesis · doi:10.1002/mc.22581 · Cited by 83
Hishikawa, Y., Abe, S., Kinugasa, S., Yoshimura, H., Monden, N., Igarashi, M., Tachibana, M., & Nagasue, N. (2009) · Oncology · doi:10.1159/000227714 · Cited by 70
Huang, J., Zhou, Y., Zhang, H., Qu, T., Mao, Y., Zhu, H., Quan, L., Xing, P., Wang, J., He, J., et al. (2012) · Medical Oncology · doi:10.1007/s12032-012-0343-4 · Cited by 68
Li, Z., Qing, Y., Guan, W., Li, M., Peng, Y., Shiheng, Z., Xiong, Y., & Wang, D. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2562-1 · Cited by 66
Guerra, F., Paiano, A., Migoni, D., Girolimetti, G., Perrone, A. M., Iaco, P. D., Fanizzi, F. P., Gasparre, G., & Bucci, C. (2019) · Cancers · doi:10.3390/cancers11010052 · Cited by 63
NRF2 Pathway Activation and Adjuvant Chemotherapy Benefit in Lung Squamous Cell Carcinoma
Cescon, D. W., She, D., Sakashita, S., Zhu, C., Pintilie, M., Shepherd, F. A., & Tsao, M. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2206 · Cited by 61
Lai, Y.-H., Kuo, C., Kuo, M. T., & Chen, H. H. W. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051486 · Cited by 54
Öhrvik, H., Logeman, B. L., Turk, B., Reinheckel, T., & Thiele, D. J. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.731281 · Cited by 52
Hypoxia Promotes Acquisition of Aggressive Phenotypes in Human Malignant Mesothelioma
Kim, M.-C., Hwang, S.-H., Kim, N.-Y., Lee, H.-S., Ji, S., Yang, Y., & Kim, Y. (2018) · BMC Cancer · doi:10.1186/s12885-018-4720-z · Cited by 49
Association of copper transporter expression with platinum resistance in epithelial ovarian cancer.
Yoshida, H., TERAMAE, M., Yamauchi, M., Fukuda, T., Yasui, T., Sumi, T., Honda, K.-I., & Ishiko, O. (2013) · PubMed · Cited by 42
Fu, S., Hou, M., Wheler, J. J., Hong, D. S., Naing, A., Tsimberidou, A. M., Jankú, F., Zinner, R., Piha-Paul, S. A., Falchook, G. S., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-0051-8 · Cited by 40
Pass, H. I., Lavilla, C., Canino, C., Goparaju, C. M. V., Preiss, J. S., Noreen, S., Blandino, G., & Cioce, M. (2016) · Oncotarget · doi:10.18632/oncotarget.10895 · Cited by 37
Abyaneh, H. S., Gupta, N., Alshareef, A., Gopal, K., Lavasanifar, A., & Lai, R. L. (2018) · Cancer Microenvironment · doi:10.1007/s12307-018-0218-0 · Cited by 34
Hwang, I. G., Jang, J.-S., Do, J. H., Kang, J. H., Lee, G. W., Oh, S. Y., Kwon, H.-C., Jun, H. J., Lim, H. Y., Lee, S., et al. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1558-3 · Cited by 30
Ma, X., Huang, J.-W., Wei, D., Hongyu, Z., Zhang, J., Shi, C., & Liu, L. (2015) · Oral Oncology · doi:10.1016/j.oraloncology.2015.02.094 · Cited by 28
Chen, S.-J., Kuo, C., Pan, H.-Y., Tsou, T., Yeh, S., & Chang, J. (2016) · Oncotarget · doi:10.18632/oncotarget.10336 · Cited by 28
Self-citationZhao, W., Xia, S., Zhang, Z., Zhang, Z.-P., You, C.-C., Yan, J., & Xu, G. (2016) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-016-2759-1 · Cited by 23
Ryu, H., Song, I., Choi, Y.-S., Yun, H., Jo, D., Kim, J., Ko, Y. B., & Lee, H. J. (2017) · Medicine · doi:10.1097/md.0000000000009402 · Cited by 23
A drug combination targeting hypoxia induced chemoresistance and stemness in glioma cells
Jalota, A., Kumar, M., Das, B. C., Yadav, A. K., Chosdol, K., & Sinha, S. (2018) · Oncotarget · doi:10.18632/oncotarget.24839 · Cited by 21
Yeh, Y., Hsu, S.-J., Lin, P., Hsu, K., Wu, P., Su, W., Chang, J., & Shen, M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1007 · Cited by 20
Self-citationVillalobos, M., Czapiewski, P., Reinmuth, N., Fischer, J. R., Andreas, S., Kortsik, C., Serke, M. H., Wolf, M., Neuser, P., Reuß, A., et al. (2018) · Medical Oncology · doi:10.1007/s12032-018-1169-5 · Cited by 9
Kudo, M., Yamamoto, Y., Koga, Y., Hamaguchi, T., Akimoto, T., Yasunaga, M., & Matsumura, Y. (2016) · Molecular and Clinical Oncology · doi:10.3892/mco.2016.1070 · Cited by 6
Cited by
Skowron, M. A., Eul, K., Stephan, A., Ludwig, G. F., Wakileh, G. A., Bister, A., Söhngen, C., Raba, K., Petzsch, P., Poschmann, G., et al. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13282 · Cited by 20
Metadata
- Authors
- Chen, S.-H., & Chang, J.-Y.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-08-24
- Volume
- 20
- Issue
- 17
- Pages
- 4136
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2969669884
- Cited by
- 428
- References
- 97
- FWCI
- 15.96
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.